Human pluripotent stem cell (hPSC)-derived models for autism spectrum disorder drug discovery.

IF 6 2区 医学 Q1 PHARMACOLOGY & PHARMACY Expert Opinion on Drug Discovery Pub Date : 2024-12-24 DOI:10.1080/17460441.2024.2416484
Lingdi Nie, Courtney Irwin, Sarah Geahchan, Karun K Singh
{"title":"Human pluripotent stem cell (hPSC)-derived models for autism spectrum disorder drug discovery.","authors":"Lingdi Nie, Courtney Irwin, Sarah Geahchan, Karun K Singh","doi":"10.1080/17460441.2024.2416484","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Autism spectrum disorder (ASD) is a prevalent and complex neurodevelopmental disorder (NDD) with genetic and environmental origins. Currently, there are no effective pharmacological treatments targeting core ASD features. This leads to unmet medical needs of individuals with ASD and requires relevant human disease models recapitulating genetic and clinical heterogeneity to better understand underlying mechanisms and identify potential pharmacological therapies. Recent advancements in stem cell technology have enabled the generation of human pluripotent stem cell (hPSC)-derived two-dimensional (2D) and three-dimensional (3D) neural models, which serve as powerful tools for ASD modeling and drug discovery.</p><p><strong>Areas covered: </strong>This article reviews the applications of hPSC-derived 2D and 3D neural models in studying various forms of ASD using pharmacological perturbation and drug screenings, highlighting the potential use of these models to develop novel pharmacological treatment strategies for ASD.</p><p><strong>Expert opinion: </strong>hPSC-derived models recapitulate early human brain development spatiotemporally and have allowed patient-specific mechanistic investigation and therapeutic development using advanced molecular technologies, which will contribute to precision medicine for ASD therapy. Improvements are still required in hPSC-based models to further enhance their physiological relevance, clinical translation, and scalability for ASD drug discovery.</p>","PeriodicalId":12267,"journal":{"name":"Expert Opinion on Drug Discovery","volume":" ","pages":"1-19"},"PeriodicalIF":6.0000,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Drug Discovery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17460441.2024.2416484","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Autism spectrum disorder (ASD) is a prevalent and complex neurodevelopmental disorder (NDD) with genetic and environmental origins. Currently, there are no effective pharmacological treatments targeting core ASD features. This leads to unmet medical needs of individuals with ASD and requires relevant human disease models recapitulating genetic and clinical heterogeneity to better understand underlying mechanisms and identify potential pharmacological therapies. Recent advancements in stem cell technology have enabled the generation of human pluripotent stem cell (hPSC)-derived two-dimensional (2D) and three-dimensional (3D) neural models, which serve as powerful tools for ASD modeling and drug discovery.

Areas covered: This article reviews the applications of hPSC-derived 2D and 3D neural models in studying various forms of ASD using pharmacological perturbation and drug screenings, highlighting the potential use of these models to develop novel pharmacological treatment strategies for ASD.

Expert opinion: hPSC-derived models recapitulate early human brain development spatiotemporally and have allowed patient-specific mechanistic investigation and therapeutic development using advanced molecular technologies, which will contribute to precision medicine for ASD therapy. Improvements are still required in hPSC-based models to further enhance their physiological relevance, clinical translation, and scalability for ASD drug discovery.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
人类多能干细胞(hPSC)衍生模型用于自闭症谱系障碍药物发现。
自闭症谱系障碍(ASD)是一种普遍而复杂的神经发育障碍(NDD),具有遗传和环境根源。目前,还没有针对ASD核心特征的有效药物治疗方法。这导致ASD患者的医疗需求未得到满足,需要相关的人类疾病模型来概括遗传和临床异质性,以更好地了解潜在的机制并确定潜在的药物治疗方法。干细胞技术的最新进展使人类多能干细胞(hPSC)衍生的二维(2D)和三维(3D)神经模型成为ASD建模和药物发现的有力工具。本文综述了hpsc衍生的2D和3D神经模型在利用药理学扰动和药物筛选研究各种形式ASD中的应用,强调了这些模型在开发新的ASD药物治疗策略方面的潜在用途。专家意见:hpsc衍生的模型概括了早期人类大脑的时空发育,并允许使用先进的分子技术进行患者特异性机制研究和治疗开发,这将有助于ASD治疗的精准医学。基于hpsc的模型仍然需要改进,以进一步增强其在ASD药物发现中的生理相关性、临床翻译和可扩展性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
10.20
自引率
1.60%
发文量
78
审稿时长
6-12 weeks
期刊介绍: Expert Opinion on Drug Discovery (ISSN 1746-0441 [print], 1746-045X [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on novel technologies involved in the drug discovery process, leading to new leads and reduced attrition rates. Each article is structured to incorporate the author’s own expert opinion on the scope for future development. The Editors welcome: Reviews covering chemoinformatics; bioinformatics; assay development; novel screening technologies; in vitro/in vivo models; structure-based drug design; systems biology Drug Case Histories examining the steps involved in the preclinical and clinical development of a particular drug The audience consists of scientists and managers in the healthcare and pharmaceutical industry, academic pharmaceutical scientists and other closely related professionals looking to enhance the success of their drug candidates through optimisation at the preclinical level.
期刊最新文献
The rules often neglected in current medicinal chemistry. Animal models of chronic obstructive pulmonary disease and their role in drug discovery and development: a critical review. The preclinical discovery and development of zanubrutinib for the treatment of chronic lymphocytic leukemia. The importance of preclinical models for cholangiocarcinoma drug discovery. Animal models of Kabuki syndrome and their applicability to novel drug discovery.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1